Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
2.650
-0.230 (-7.99%)
Mar 11, 2025, 4:00 PM EST - Market closed
Larimar Therapeutics Employees
Larimar Therapeutics had 42 employees as of December 31, 2023. The number of employees increased by 16 or 61.54% compared to the previous year.
Employees
42
Change (1Y)
16
Growth (1Y)
61.54%
Revenue / Employee
n/a
Profits / Employee
-$1,542,214
Market Cap
169.09M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | 16 | 61.54% |
Dec 31, 2022 | 26 | -5 | -16.13% |
Dec 31, 2021 | 31 | 3 | 10.71% |
Dec 31, 2020 | 28 | 12 | 75.00% |
Dec 31, 2019 | 16 | - | - |
LRMR News
- 8 days ago - Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - GlobeNewsWire
- 2 months ago - Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better - Seeking Alpha
- 3 months ago - What's Going On With Larimar Therapeutics Stock On Tuesday? - Benzinga
- 3 months ago - Why Is Larimar Therapeutics Stock Trading Lower On Monday? - Benzinga
- 3 months ago - Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - GlobeNewsWire
- 4 months ago - Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 5 months ago - Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga